Profile data is unavailable for this security.
About the company
Medico Remedies Limited is an India-based pharmaceutical formulation manufacturing company. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. It has manufacturing and marketing capabilities in formulation with focus on anti-infective, Beta-Lactums, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements. In addition, the Company also manufactures other drugs, such as non-steroidal anti-inflammatory drugs (NSAIDS), antihistaminic, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments. Its products include Doxycycline Capsules, Zenof-400 (Ofloxacin Tablets 400mg), Azithromycin Tablets, Aciclovir Tablets, Cipta Tablets, Cotrimoxazole Tablets, Tos Syrup, Paediatric Co-Trimozole Oral, Med Reactin (Cyproheptadine), and Medivit Syrup, among others.
- Revenue in INR (TTM)1.44bn
- Net income in INR85.50m
- Incorporated1994
- Employees193.00
- LocationMedico Remedies Ltd1105/1106, 11Th Floor, Hubtown Solaris,Andheri (East), N.S.Phadke MargTHANE 401404IndiaIND
- Phone+91 8 046047706
- Fax+91 2 226281059
- Websitehttps://www.medicoremediesindia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd | 1.04bn | 182.71m | 3.63bn | 122.00 | 19.84 | 3.75 | 16.60 | 3.48 | 14.86 | 14.86 | 84.62 | 78.64 | 0.9851 | 7.61 | 5.20 | 8,531,213.00 | 17.29 | 13.52 | 20.01 | 16.46 | 66.70 | 43.71 | 17.55 | 13.42 | 2.87 | 205.06 | 0.00 | -- | -0.1132 | 15.60 | 27.94 | 42.01 | 77.72 | -- |
| Brooks Laboratories Ltd | 817.15m | -175.35m | 3.65bn | 293.00 | -- | -- | -- | 4.47 | -6.84 | -6.84 | 31.86 | -- | -- | -- | -- | 2,788,911.00 | -- | -13.86 | -- | -22.90 | 29.09 | 26.19 | -21.46 | -27.47 | -- | 0.0861 | -- | -- | 25.76 | 7.63 | 6.26 | -- | -12.73 | -- |
| SMS Lifesciences India Ltd | 3.24bn | 178.73m | 4.15bn | 574.00 | 23.25 | -- | 12.91 | 1.28 | 59.10 | 59.10 | 1,070.58 | -- | -- | -- | -- | 5,642,058.00 | -- | 4.08 | -- | 6.73 | 34.82 | 29.68 | 5.33 | 4.46 | -- | 2.88 | -- | 2.61 | -3.04 | -4.13 | -20.68 | -12.62 | -3.09 | 0.00 |
| Venus Remedies Ltd. | 6.15bn | 221.01m | 4.16bn | 1.19k | 18.81 | 0.8424 | 8.87 | 0.6772 | 16.56 | 16.56 | 461.13 | 369.72 | 0.945 | 2.68 | 8.72 | 5,178,093.00 | 3.40 | 4.82 | 4.06 | 6.17 | 39.06 | 38.90 | 3.60 | 5.58 | 2.69 | 1,660.39 | 0.0765 | -- | 8.27 | 13.32 | 7.25 | -- | 6.38 | -- |
| Medico Remedies Ltd | 1.44bn | 85.50m | 4.79bn | 193.00 | 56.83 | -- | 41.78 | 3.32 | 1.02 | 1.02 | 17.15 | -- | -- | -- | -- | 7,474,037.00 | -- | 6.15 | -- | 12.40 | 25.07 | 25.26 | 5.93 | 3.99 | -- | 12.49 | -- | -- | 3.19 | 8.21 | 14.49 | 39.49 | -7.58 | -- |
| ZIM Laboratories Ltd | 3.82bn | 179.18m | 5.15bn | 556.00 | 28.78 | -- | 14.79 | 1.35 | 3.67 | 3.67 | 77.81 | -- | -- | -- | -- | 6,867,013.00 | -- | 3.88 | -- | 6.54 | 53.76 | 47.45 | 4.69 | 3.97 | -- | 3.44 | -- | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Kilitch Drugs (India) Ltd | 1.51bn | 125.85m | 5.16bn | 168.00 | 40.87 | -- | 36.74 | 3.41 | 7.85 | 7.85 | 94.36 | -- | -- | -- | -- | 9,003,994.00 | -- | 3.38 | -- | 4.76 | 36.87 | 35.33 | 7.03 | 6.17 | -- | 2.63 | -- | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| Lyka Labs Ltd | 1.18bn | 7.97m | 5.18bn | 423.00 | 794.40 | -- | 44.28 | 4.37 | 0.1826 | 0.1826 | 35.62 | -- | -- | -- | -- | 2,799,802.00 | -- | -5.48 | -- | -8.30 | 60.45 | 60.82 | 0.5065 | -9.16 | -- | 1.36 | -- | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| Accent Microcell Ltd | 2.62bn | 325.33m | 5.48bn | 174.00 | 13.15 | 3.08 | 15.28 | 2.09 | 19.80 | 19.80 | 141.04 | 84.68 | 1.65 | 4.64 | 6.67 | 15,070,950.00 | 20.43 | -- | 24.77 | -- | 32.30 | -- | 12.41 | -- | 4.81 | -- | 0.0114 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
